[HTML][HTML] Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes
O Devinsky, C Verducci, EA Thiele, LC Laux… - Epilepsy & Behavior, 2018 - Elsevier
Objective We studied our collective open-label, compassionate use experience in using
cannabidiol (CBD) to treat epilepsy in patients with CDKL5 deficiency disorder and Aicardi,
Doose, and Dup15q syndromes. Methods We included patients aged 1–30 years with
severe childhood-onset epilepsy who received CBD for≥ 10 weeks as part of multiple
investigator-initiated expanded access or state access programs for a compassionate
prospective interventional study: CDKL5 deficiency disorder (n= 20), Aicardi syndrome (n …
cannabidiol (CBD) to treat epilepsy in patients with CDKL5 deficiency disorder and Aicardi,
Doose, and Dup15q syndromes. Methods We included patients aged 1–30 years with
severe childhood-onset epilepsy who received CBD for≥ 10 weeks as part of multiple
investigator-initiated expanded access or state access programs for a compassionate
prospective interventional study: CDKL5 deficiency disorder (n= 20), Aicardi syndrome (n …